Abstracts tagged "antiphospholipid syndrome and pregnancy"

Abstract Number: 141 • 2019 ACR/ARP Annual Meeting
Pregnancy in Antiphospholipid Syndrome: Outcomes and Risk Factors – Data from a Portuguese Multidisclinary Unit
Agna Neto¹, Patrícia Martins ², Mónica Centeno ³, Cláudia Araújo ³, Luísa Pinto ³ and Susana Capela ², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon; Hospital Central do Funchal, Madeira., Lisbon, Portugal, ²Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHULN; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ³Departamento de Ginecologia, Obstetrícia e Medicina da Reprodução, Hospital de Santa Maria, CHLN, Lisbon, Portugal
Background/Purpose: Women with antiphospholipid syndrome (APS) are at increased risk of recurrent miscarriage, fetal death, placental insufficiency, preeclampsia and fetal growth restriction (FGR). Although treatment…
Abstract Number: 12 • 2014 ACR/ARHP Annual Meeting
Non-Criteria Antiphospholipid Antibodies in Obstetrical “seronegative Anti-Phospholipid syndrome”
Arsene Mekinian¹, Marie Charlotte Bourrienne², Lionel Carbillon³, Sabine Grootenboer², Luc Dechaisemartin⁴, Sylvie chollet Martin², Olivier Fain⁵ and Pascale Nicaise-Roland⁶, ¹Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³Service de gynécologie-obstétrique, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, ⁴Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, PARIS, France, ⁵Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ⁶Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, Paris, France
Background/Purpose The aims of our prospective study were to determine the prevalence of non-criteria aPL and their clinical relevance in a seronegative population with pregnancy…
Abstract Number: 6 • 2013 ACR/ARHP Annual Meeting
Researchers’ Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome
Lidia Ostanek¹, Danuta Bobrowska - Snarska², Barbara Nestorowicz³ and Marek Brzosko⁴, ¹Department of Rheumatology and Internal Diseases, Pomeranian Medical University, Szczecin, Poland, Szczecin, Poland, ²Department of Rheumatology, Pomeranian Medical University, Szczecin, Poland, Szczecin, Poland, ³Department of Pathological Obstetrics and Delivery, Pomeranian Medical University , Szczecin, Poland, Szczecin, Poland, ⁴Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland
Background/Purpose: To analyse risk factors for obstetric pathology in patients with antiphospholipid syndrome (APS). To assess the effectiveness of treatment depending on pharmacotherapy. Methods:…
Abstract Number: 1736 • 2012 ACR/ARHP Annual Meeting
The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity
Cecilia B. Chighizola¹, Guilherme Ramires de Jesus², Laura Andreoli³, Alessandra Banzato⁴, Guillermo J. Pons-Estel⁵, Michael D. Lockshin⁶, Doruk Erkan⁷ and On Behalf of APS Action⁸, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ²Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Rheumatology Unit, University of Brescia, Brescia, Italy, ⁴Department of Cardiac Thoracic and Vascular Sciences, (2) Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua Italy, Padua, Italy, ⁵Servicio de Enfermedades Autoinmunes, (4) Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁶Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network created to conduct well-designed clinical trials in persistently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].